Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Catalent stock | $131.78

Learn how to easily invest in Catalent stock.

Catalent Inc is a drug manufacturers-specialty & generic business based in the US. Catalent shares (CTLT) are listed on the NYSE and all prices are listed in US Dollars. Catalent employs 17,300 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Catalent

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTLT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Catalent stock price (NYSE: CTLT)

Use our graph to track the performance of CTLT stocks over time.

Catalent shares at a glance

Information last updated 2021-10-15.
Latest market close$131.78
52-week range$86.43 - $142.64
50-day moving average $134.54
200-day moving average $116.79
Wall St. target price$150.92
PE ratio 41.4051
Dividend yield N/A (0%)
Earnings per share (TTM) $3.11

Buy Catalent shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catalent stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalent price performance over time

Historical closes compared with the close of $131.78 from 2021-10-20

1 week (2021-10-14) 2.20%
1 month (2021-09-21) -3.17%
3 months (2021-07-21) 16.06%
6 months (2021-04-21) 18.43%
1 year (2020-10-21) 42.60%
2 years (2019-10-21) 170.98%
3 years (2018-10-19) 218.54%
5 years (2016-10-21) 440.75%

Is Catalent under- or over-valued?

Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalent's P/E ratio

Catalent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Catalent shares trade at around 41x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Catalent's PEG ratio

Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1046. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalent's EBITDA

Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $954 million.

The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.

Catalent financials

Revenue TTM $4 billion
Operating margin TTM 16.63%
Gross profit TTM $1.4 billion
Return on assets TTM 4.92%
Return on equity TTM 15.04%
Profit margin 14.63%
Book value $22.96
Market capitalisation $22 billion

TTM: trailing 12 months

Shorting Catalent shares

There are currently 2.1 million Catalent shares held short by investors – that's known as Catalent's "short interest". This figure is 2.6% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Catalent shares can be evaluated.

Catalent's "short interest ratio" (SIR)

Catalent's "short interest ratio" (SIR) is the quantity of Catalent shares currently shorted divided by the average quantity of Catalent shares traded daily (recently around 1.1 million). Catalent's SIR currently stands at 1.86. In other words for every 100,000 Catalent shares traded daily on the market, roughly 1860 shares are currently held short.

However Catalent's short interest can also be evaluated against the total number of Catalent shares, or, against the total number of tradable Catalent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalent's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Catalent shares in existence, roughly 10 shares are currently held short) or 0.0125% of the tradable shares (for every 100,000 tradable Catalent shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalent.

Find out more about how you can short Catalent stock.

Catalent share dividends

We're not expecting Catalent to pay a dividend over the next 12 months.

Catalent share price volatility

Over the last 12 months, Catalent's shares have ranged in value from as little as $86.43 up to $142.64. A popular way to gauge a stock's volatility is its "beta".

CTLT.US volatility(beta: 1.39)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.3889. This would suggest that Catalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalent overview

Catalent, Inc. , together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services.

Frequently asked questions

What percentage of Catalent is owned by insiders or institutions?
Currently 0.309% of Catalent shares are held by insiders and 102.736% by institutions.
How many people work for Catalent?
Latest data suggests 17,300 work at Catalent.
When does the fiscal year end for Catalent?
Catalent's fiscal year ends in June.
Where is Catalent based?
Catalent's address is: 14 Schoolhouse Road, Somerset, NJ, United States, 08873
What is Catalent's ISIN number?
Catalent's international securities identification number is: US1488061029
What is Catalent's CUSIP number?
Catalent's Committee on Uniform Securities Identification Procedures number is: 148806102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site